In addition to underpinning resistance to AR-targeted therapy, induction of CXCL8 signalling modulates the sensitivity of prostate cancer cells to several novel molecular targeted therapies and chemotherapeutic agents, including oxaliplatin that induces DNA double-strand breaks in CaP cells (23). Here, AR is linked to prostate cancer.